THE DEAL, AT A GLANCE
From the announcementMicrobiotica
01What it doesMicrobiotica is advancing programmes in immuno-oncology and inflammatory bowel disease, including MB097 for advanced melanoma and MB310 for ulcerative colitis.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02What happenedMicrobiotica raised Series C, announced 2026-10-16From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Microbiotica · Financing Record
Explore source-linked visual explanations for Microbiotica. Unsupported claims are withheld while source review continues.
Record 14149 · Recorded date: 2026-10-16
What it does
Unsupported business claims are withheld pending source review. Explore the linked records for available evidence.
Explore company records →